Study of efficacy of prazocin on patient with post traumatic stress disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012085341N1

Enrollment

100

Registered

2011-04-13

Start date

2011-01-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post traumatic stress disorder. Post-traumatic stress disorder

Interventions

Intervention 1: first group: prazosine 1-5 mg for 8 weeks. Intervention 2: second group: hydrocizine 10-100 mg for 8 weeks. Intervention 3: third group: placebo.

Treatment - Drugs

Placebo

first group: prazosine 1-5 mg for 8 weeks

second group: hydrocizine 10-100 mg for 8 weeks

third group: placebo

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients who have post traumatic stress disorder, age under 45 year, absence of heart disease, not having history of substances abuses. Exclusion criteria: hypotension during treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sleep disorders. Timepoint: with 3 months interval. Method of measurement: Pittursburgs Sleep Quality Index.	—

Secondary

Measure	Time frame
Sleep enhancement. Timepoint: with 3 months interval. Method of measurement: Pittursburgs Sleep Quality Index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sabzehee

Hamadan University of Medical Sciences

p.sabzeie@umsha.ac.ir+98 81 1828 5015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026